keyword
lung
transplant
immunocompromis
infecti
complic
cytomegaloviru
aspergillosi
prophylaxi
lung
transplant
recipi
higher
risk
infecti
complic
recipi
solid
organ
major
caus
mortal
beyond
year
lung
transplant
bronchiol
obliteran
syndrom
chronic
allograft
reject
infect
cytomegaloviru
cmv
pseudomona
aeruginosa
aspergillu
speci
associ
develop
bronchiol
obliteran
syndrom
cmv
fungal
prophylaxi
regimen
vari
transplant
center
pneuomcysti
jiroveci
pneumonia
rare
era
prophylaxi
lung
transplant
procedur
report
intern
societi
heart
lung
transplant
endstag
lung
diseas
highest
annual
number
date
surviv
lung
transplant
recipi
continu
lag
behind
solid
organ
transplant
recipi
median
surviv
halflif
year
graft
failur
noncytomegaloviru
noncmv
infect
remain
major
report
caus
postop
mortal
first
year
transplant
first
year
common
identifi
caus
mortal
bronchiol
obliteran
syndrom
bo
noncmv
infect
immunosuppress
contribut
significantli
posttranspl
infect
recipi
howev
lung
transplant
recipi
gener
intens
immunosuppress
solid
organ
recipi
frequent
sever
infecti
complic
addit
factor
preoper
microorgan
colon
transmiss
infecti
agent
donor
organ
blunt
cough
mechan
due
denerv
impair
mucociliari
clearanc
poor
lymphat
drainag
ischem
larg
airway
immedi
postop
period
constant
exposur
environ
uniqu
place
lung
transplant
recipi
higher
risk
infect
organ
recipi
chronic
allograft
reject
form
bo
major
lifelimit
complic
lung
transplant
pulmonari
infect
virus
includ
cmv
gramneg
bacilli
especi
pseudomona
aeruginosa
aspergillu
speci
associ
increas
risk
bo
find
underscor
import
prevent
diagnosi
treatment
infect
popul
undergon
lung
transplant
periop
period
lung
transplant
recipi
increas
risk
bacteri
fungal
viral
infect
patient
popul
gramneg
organ
includ
p
aeruginosa
methicillinresist
staphylococcu
aureu
mrsa
often
encount
infect
result
chronic
preoper
recipi
colon
common
suppur
condit
cystic
fibrosi
cf
mechan
includ
acut
periop
donor
colon
infect
postop
infect
earli
recipi
via
mechan
ventil
mean
throughout
initi
hospit
stay
donor
airway
sputum
specimen
typic
obtain
cultur
patient
implant
result
gram
stain
cultur
donor
sputum
follow
ensur
initi
antibiot
regimen
appropri
cover
organ
identifi
donor
airway
specimen
transplant
recipi
colon
known
organ
periop
antibiot
prophylaxi
base
result
prior
cultur
sensit
data
especi
import
patient
cf
noncf
bronchiectasi
patient
often
chronic
infect
multidrugresist
organ
patient
place
wait
list
lung
transplant
periop
antibiot
regimen
usual
plan
ahead
time
addit
result
bacteri
cultur
recent
posit
cultur
aspergillu
speci
nontubercul
mycobacteria
consid
select
periop
antimicrobi
regimen
patient
without
previou
airway
cultur
prophylact
periop
antibiot
therapi
must
provid
coverag
multidrugresist
gramneg
organ
mrsa
center
patient
initi
antipseudomon
blactam
eg
cefepim
maxipim
meropenem
merrem
piperacillintazobactam
zosyn
vancomycin
periop
choic
antipseudomon
agent
base
local
sensit
institut
antibiot
combin
continu
day
unless
indic
longer
cours
therapi
aris
postop
period
surgic
site
infect
postop
period
commonli
caus
skin
flora
frequent
organ
staphylococcu
aureu
patient
colon
gramneg
organ
preoper
surgic
complic
develop
pleural
less
commonli
mediastin
infecti
complic
postop
period
ischem
airway
injuri
major
risk
factor
develop
aspergillu
tracheobronch
rare
occurr
challeng
surgic
site
infect
observ
recipi
multidrugresist
organ
present
preoper
seem
logic
although
larg
support
evid
patient
undergo
longer
vigor
infecti
prophylaxi
fungal
colon
infect
commonli
candida
speci
aspergillu
speci
occur
periop
period
candida
albican
remain
common
candida
speci
isol
lung
transplant
recipi
although
recent
rise
nonalbican
speci
sometim
difficult
distinguish
invas
candid
infect
airway
colon
center
usual
treat
patient
either
fluconazol
diflucan
echinocandin
ischem
airway
injuri
copiou
secret
candida
speci
organ
cultur
major
risk
factor
aspergillu
infect
previou
colon
ischem
airway
injuri
tabl
outlin
common
prophylaxi
regimen
viral
fungal
pneumocysti
jiroveci
infect
contrast
nontranspl
host
patient
undergon
lung
transplant
much
higher
risk
becom
colon
infect
drugresist
organ
gramneg
organ
frequent
caus
bacteri
pneumonia
p
aeruginosa
common
gramneg
organ
identifi
less
frequent
includ
limit
acinetobact
baumannii
escherichia
coli
klebsiella
pneumonia
stenotrophomona
maltophilia
burkholderia
cepacia
serratia
marcescen
de
novo
colon
airway
p
aeruginosa
transplant
demonstr
independ
risk
factor
develop
bo
staphylococcu
aureu
common
gramposit
organ
caus
pneumonia
second
common
specif
organ
caus
bacteri
pneumonia
among
lung
transplant
recipi
infect
b
cepacia
histor
associ
poor
outcom
transplant
mani
center
consid
chronic
infect
b
cepacia
absolut
contraind
lung
transplant
howev
sinc
recogn
organ
formal
classifi
b
cepacia
repres
group
complex
b
cepacia
complex
bcc
compris
sever
distinct
speci
genomovar
burkholderia
cenocepacia
genomovar
iii
burkholderia
multivoran
genomovar
ii
account
major
infect
b
cenocepacia
associ
much
higher
risk
posttranspl
mortal
includ
higher
risk
death
year
compar
patient
infect
bcc
organ
b
cenocepacia
higher
risk
death
year
compar
patient
infect
bcc
organ
seri
bcc
infect
organ
b
cenocepacia
increas
risk
death
transplant
comparison
patient
infect
bcc
b
cenocepacia
caus
pneumonia
local
invas
diseas
empyema
dissemin
infect
although
member
bcc
burkholderia
gladioli
also
associ
increas
mortal
transplant
center
consid
specif
speci
burkholderia
risk
b
cenocepacia
infect
evalu
patient
cf
infect
organ
lung
transplant
recipi
immunocompromis
lifelong
empir
antibiot
treatment
lung
recipi
pneumonia
includ
coverag
mrsa
p
aeruginosa
atyp
organ
listeria
mycoplasma
chlamydia
base
patient
clinic
statu
bronchoscopi
bronchoalveolar
lavag
without
transbronchi
biopsi
consid
addit
cultur
data
bronchoscopi
help
evalu
noninfecti
caus
short
breath
abnorm
chest
radiographi
includ
airway
complic
acut
chronic
reject
lung
transplant
recipi
often
requir
day
antibiot
therapi
longer
recoveri
slow
airway
cultur
remain
posit
patient
pneumonia
spectrum
antibiot
therapi
narrow
base
cultur
result
possibl
cmv
infect
signific
caus
morbid
transplant
recipi
among
lung
recipi
cmv
common
opportunist
infect
major
risk
factor
develop
cmv
diseas
interact
cmv
statu
recipi
cmv
statu
donor
patient
cmv
neg
receiv
cmvneg
donor
organ
r
low
risk
cmv
infect
cmvposit
recipi
receiv
either
cmvposit
cmvneg
allograft
r
r
medium
risk
cmvneg
recipi
receiv
cmvposit
allograft
r
highest
risk
develop
cmv
diseas
cmv
infect
commonli
occur
within
first
month
transplant
risk
wane
first
year
recipi
unless
immunosuppress
regimen
augment
howev
minor
recipi
recurr
cmv
infect
beyond
first
year
transplant
result
increas
morbid
mortal
cmv
prophylaxi
may
delay
onset
invas
diseas
gener
main
prophylact
strategi
practic
specif
center
highli
variabl
center
advoc
valganciclovir
valcyt
intraven
ganciclovir
cytoven
month
highrisk
recipi
r
encourag
lifelong
prophylaxi
contrast
controversi
exist
optim
approach
recipi
medium
risk
r
r
cmv
diseas
one
strategi
involv
univers
prophylaxi
atrisk
patient
second
strategi
base
monitor
preemptiv
therapi
time
identif
activ
viral
replic
ideal
symptomat
infect
use
strategi
mediumrisk
patient
monitor
frequent
twice
weekli
screen
either
viral
antigenemia
plasma
polymeras
chain
reaction
pcr
cmv
assay
vari
differ
virolog
laboratori
test
differ
threshold
posit
present
fewer
center
reli
test
antigenemia
pcr
assay
becom
wide
avail
less
prone
technic
error
treatment
cmv
infect
start
first
sign
viral
replic
concern
prophylact
therapi
center
either
start
intraven
ganciclovir
transit
oral
valganciclovir
administ
oral
valganciclovir
outset
valganciclovir
typic
administ
dose
mg
oral
daili
prophylaxi
patient
normal
renal
function
dose
may
need
adjust
set
low
bodi
mass
leukopenia
frequent
advers
effect
ganciclovir
valganciclovir
therapi
leukopenia
thrombocytopenia
also
small
risk
ganciclovir
resist
patient
prophylaxi
especi
treatment
period
interrupt
addit
limit
prophylaxi
given
time
cours
shift
timelin
cmv
diseas
later
time
point
transplant
cmvspecif
immunoglobulin
cytogam
use
center
part
prophylact
regimen
highrisk
patient
random
control
trial
demonstr
superior
univers
prophylaxi
preemptiv
strategi
howev
one
larg
multicent
trial
demonstr
atrisk
patient
month
prophylaxi
valganciclovir
superior
month
month
followup
respect
cmv
infect
chang
acut
reject
cmv
ganciclovir
resist
mutat
laboratori
abnorm
term
cmv
infect
appli
situat
viral
replic
identifi
cmv
diseas
indic
cmv
infect
symptom
includ
mononucleosislik
syndrom
fever
malais
fatigu
organspecif
invas
involv
lung
fig
liver
gastrointestin
tract
central
nervou
system
retina
discuss
earlier
univers
standard
viral
load
cutoff
repres
posit
blood
pcr
result
howev
symptom
present
gener
consensu
initi
treatment
cmv
infect
standard
therapi
includ
intraven
ganciclovir
mgkg
twice
daili
oral
valganciclovir
mg
twice
daili
dose
adjust
renal
function
leukocyt
count
oral
valganciclovir
shown
noninferior
intraven
ganciclovir
mix
popul
transplant
recipi
consid
initi
therapi
especi
patient
subclin
cmv
infect
mild
diseas
antivir
therapi
gener
continu
least
week
viral
replic
longer
detect
cmvspecif
immunoglobulin
use
addon
therapi
sever
case
patient
respond
initi
therapi
especi
seroneg
recipi
patient
respond
convent
therapi
resist
ganciclovir
must
evalu
ul
gene
encod
protein
kinas
involv
phosphoryl
activ
ganciclovir
mutat
within
gene
common
mechan
ganciclovir
resist
mutat
within
region
encod
cmv
dna
polymeras
also
confer
ganciclovir
resist
like
result
resist
cidofovir
foscarnet
mani
patient
ul
mutat
mutat
respond
therapi
cidofovir
foscarnet
howev
drug
toxic
major
obstacl
treatment
communityacquir
respiratori
viru
carv
infect
includ
respiratori
syncyti
viru
rsv
influenza
parainfluenza
rhinoviru
adenoviru
associ
increas
risk
bo
death
carv
identifi
includ
human
metapneumoviru
coronaviru
bocaviru
role
virus
develop
bo
yet
establish
given
influenza
infect
treatabl
import
evalu
patient
clinic
symptom
typic
influenza
season
treat
accordingli
nontranspl
recipi
firstlin
therapi
influenza
lung
transplant
recipi
neuraminidas
inhibitor
oseltamivir
tamiflu
sever
ill
high
durat
therapi
often
extend
beyond
convent
day
day
decis
treat
rsv
ribavirin
either
inhal
system
vari
center
center
individu
patient
rsv
season
overlap
influenza
season
may
extend
later
spring
patient
rsv
goal
reduc
progress
upper
respiratori
tract
infect
lower
respiratori
tract
infect
thu
risk
bo
given
risk
addit
high
clinic
suspicion
influenza
patient
upper
respiratori
tract
symptom
winter
earli
spring
test
rsv
well
center
patient
posit
result
nasopharyng
viral
swab
rsv
treat
day
inhal
ribavirin
therapi
intraven
ribavirin
therapi
limit
drug
toxic
especi
hemolyt
anemia
treatment
modal
includ
palivizumab
immunomodul
rsvspecif
monoclon
antibodi
intraven
immunoglobulin
ivig
rsvivig
longer
commerci
avail
evalu
children
hematopoiet
stem
cell
transplant
recipi
agent
seem
decreas
viral
load
anim
studi
shown
trend
toward
efficaci
clinic
trial
stem
cell
transplant
popul
howev
data
exist
lung
transplant
recipi
epsteinbarr
viru
ebv
agent
commonli
caus
infecti
mononucleosi
transplant
recipi
major
morbid
ebv
posttranspl
lymphoprolif
disord
ptld
major
subtyp
ptld
polymorph
ptld
character
monoclon
bcell
popul
variou
stage
matur
reactiv
cell
monomorph
ptld
character
homogen
sheet
transform
monoclon
b
cell
frequent
cytogenet
abnorm
monomorph
ptld
subtyp
nonhodgkin
lymphoma
ptld
occur
set
immunosuppress
evid
ebv
infect
identifi
mani
patient
ptld
ptld
frequent
occur
first
year
transplant
present
year
later
among
transplant
recipi
undergon
heart
lung
transplant
highest
risk
develop
ptld
like
relat
higher
intens
immunosuppress
maintain
patient
report
incid
ptld
lung
transplant
vari
recent
seri
identifi
case
patient
undergon
lung
transplant
singl
center
ptld
frequent
occur
transplant
organ
lung
recipi
neoplasm
present
solitari
multipl
pulmonari
nodul
mass
hilar
mediastin
lymphadenopathi
pleural
effus
gener
case
ptld
develop
first
year
lung
transplant
tend
isol
chest
case
develop
beyond
first
year
transplant
tend
extrathorac
often
involv
abdomen
pelvi
noteworthi
late
extrathorac
case
tend
wors
prognosi
less
like
respond
deescal
immunosuppress
diagnosi
ptld
requir
tissu
examin
similar
evalu
lymphoma
excision
biopsi
ideal
serum
pcr
test
ebv
evalu
tool
aid
diagnosi
followup
patient
ptld
specif
posit
test
patient
ptld
near
sensit
report
low
mani
patient
patholog
confirm
ptld
neg
serum
ebv
pcr
result
initi
treatment
ptld
gener
deescal
immunosuppress
increas
risk
allograft
reject
approach
monoclon
antibodi
rituximab
rituxan
next
line
therapi
ptld
rituximab
use
remiss
achiev
reduc
immunosuppress
addit
recent
studi
suggest
administ
rituximab
earlier
cours
ptld
improv
respons
durat
remiss
reduc
immunosuppress
administr
rituximab
induc
remiss
ptld
system
chemotherapi
chop
cyclophosphamid
doxorubicin
vincristin
prednison
usual
administ
surgic
resect
cur
case
ptld
local
diseas
radiat
therapi
also
consid
case
local
diseas
amen
surgic
resect
perform
surgeri
radiat
combin
reduct
immunosuppress
without
rituximab
antifung
prophylaxi
immedi
posttranspl
period
vari
wide
center
center
variat
demonstr
survey
lung
transplant
center
publish
univers
prophylaxi
target
prophylaxi
patient
colon
aspergillu
speci
transplant
becom
colon
transplant
common
approach
survey
regimen
use
differ
center
includ
inhal
amphotericin
b
without
azol
usual
itraconazol
sporanox
itraconazol
alon
fluconazol
alon
univers
voriconazol
vfend
prophylaxi
shown
decreas
incid
invas
aspergillosi
year
comparison
target
prophylaxi
itraconazol
without
inhal
amphotericin
b
howev
increas
advers
event
treatment
group
predominantli
elev
serum
liver
enzym
level
suggest
hepat
toxic
center
practic
target
approach
use
itraconazol
voriconazol
patient
colon
aspergillu
transplant
immedi
transplant
addit
patient
administ
prophylaxi
nystatin
fluconazol
oropharyng
thrush
corticosteroid
dose
taper
aspergillu
fumigatu
caus
fungal
infect
lung
transplant
recipi
howev
speci
includ
aspergillu
flavu
aspergillu
niger
aspergillu
terreu
aspergillu
ustu
increasingli
report
caus
invas
fungal
infect
aspergillu
infect
classifi
local
airway
infect
invas
diseas
invas
diseas
includ
aspergillu
tracheobronch
invas
pulmonari
aspergillosi
dissemin
aspergillosi
aspergillu
tracheobronch
character
involv
anastomot
site
distal
airway
especi
area
ischem
injuri
without
extens
lung
parenchyma
necrosi
ulcer
pseudomembran
format
characterist
featur
aspergillu
tracheobronch
diagnosi
made
use
bronchoscopi
risk
develop
aspergillu
tracheobronch
highest
first
month
transplant
progress
infect
possibl
treatment
delay
contrast
stem
cell
transplant
popul
patient
undergon
solid
organ
transplant
develop
invas
pulmonari
aspergillosi
regularli
demonstr
characterist
halo
sign
radiolog
find
comput
tomographi
chest
common
radiolog
find
nonspecif
includ
focal
multifoc
consolid
infiltr
nodular
lesion
without
cavit
fig
diagnosi
invas
aspergillu
infect
base
appropri
clinic
sign
symptom
combin
patholog
microbiolog
confirm
aspergillu
galactomannan
antigen
assay
use
marker
angioinvas
diseas
especi
stem
cell
recipi
popul
sensit
assay
diagnosi
invas
diseas
lung
transplant
recipi
report
especi
poor
patient
fig
bilater
lung
transplant
recipi
develop
thickwal
right
lower
lobe
caviti
confirm
due
invas
aspergillosi
histolog
recipi
develop
respiratori
failur
pneumothorax
respond
therapi
tracheobronch
test
bronchoalveolar
fluid
presenc
galactomannan
antigen
appear
sensit
test
serum
look
tracheobronch
invas
pulmonari
aspergillosi
howev
overal
clinic
condit
patient
must
consid
decid
one
diagnost
test
make
diagnosi
invas
aspergillosi
falseposit
result
serum
galactomannan
assay
occur
presenc
certain
antibiot
especi
piperacillintazobactam
treatment
aspergillu
infect
involv
use
azol
echinocandin
amphotericin
b
gener
depend
sever
ill
lipid
formul
amphotericin
b
remain
first
line
treatment
sever
diseas
emerg
data
echinocandin
caspofungin
cancida
micafungin
mycamin
anidulafungin
eraxi
alon
combin
voriconazol
may
effect
firstlin
treatment
pulmonari
aspergillosi
significantli
less
toxic
voriconazol
gener
prefer
itraconazol
given
predic
bioavail
voriconazol
itraconazol
posaconazol
noxafil
also
activ
aspergillu
speci
much
experi
agent
avail
intraven
formul
addit
azol
potent
interact
calcineurin
inhibitor
cyclosporin
neoral
tacrolimu
prograf
dose
need
significantli
reduc
itraconazol
voriconazol
initit
candida
speci
infect
c
albican
remain
common
candida
speci
caus
fungal
infect
lung
transplant
recipi
shift
toward
nonalbican
speci
observ
clinic
pattern
candidiasi
lung
transplant
recipi
rang
mucocutan
invas
diseas
candidemia
multiorgan
involv
although
c
albican
gener
sensit
azol
agent
includ
fluconazol
nonalbican
candida
speci
resist
fluconazol
sever
recent
studi
demonstr
effect
echinocandin
invas
candidiasi
consid
firstlin
treatment
pend
identif
speciat
candida
speci
cultur
amphotericin
b
effect
invas
candidiasi
howev
given
toxic
effect
safer
echinocandin
azol
reserv
treatment
failur
patient
intoler
echinocandin
infect
organ
resist
azol
agent
p
jiroveci
p
jiroveci
formerli
pneumocysti
carinii
organ
ubiquit
environ
caus
pneumonia
immunosuppress
patient
era
prophylaxi
rare
patient
develop
p
jiroveci
pneumonia
firstlin
prophylact
trimethoprimsulfamethoxazol
bactrim
septra
although
patient
allerg
sulfa
drug
altern
option
includ
inhal
pentamidin
pentam
atovaquon
mepron
dapson
infect
treat
high
dose
trimethoprimsulfamethoxazol
often
increas
corticosteroid
dose
especi
complic
hypoxemia
patient
allerg
sulfa
drug
desensit
consid
order
use
trimethoprimsulfamethoxazol
either
prophylaxi
treatment
event
pneumocysti
pneumonia
mani
fungal
pathogen
associ
clinic
diseas
lung
transplant
recipi
cryptococcu
neoforman
infect
lung
addit
caus
dissemin
multisystem
diseas
depend
geographi
endem
fungi
caus
diseas
lung
transplant
recipi
eg
histoplasmosi
coccidioidomycosi
blastomycosi
addit
sever
nonaspergillu
myceli
fungi
includ
zygomycet
eg
mucormycosi
scedosporium
speci
recent
recogn
import
pathogen
transplant
recipi
popul
gener
associ
worsen
outcom
compar
aspergillu
speci
nontuberculosi
mycobacteri
infect
lung
transplant
gener
observ
patient
bronchiectasi
especi
cf
preval
organ
report
patient
adult
onset
bronchiectasi
patient
cf
risk
recurr
nontuberculosi
mycobacteri
infect
signific
clinic
diseas
seem
highest
mycobacterium
abscessu
although
one
studi
posttranspl
cours
affect
abscessu
infect
although
difficult
manag
possibl
success
treat
infect
caus
mycobacterium
aviumintracellular
fig
abscessu
lung
transplant
recipi
treatment
guid
american
thorac
societi
at
infecti
diseas
societi
america
idsa
statement
regard
nontubercul
mycobacteri
diseas
nontranspl
immunocompet
host
transplant
recipi
evalu
latent
infect
mycobacterium
tuberculosi
use
tuberculin
skin
test
event
posit
test
result
evid
activ
tuberculosi
chest
radiograph
inh
therapi
administ
month
activ
tuberculosi
treat
accord
atscent
diseas
controlidsa
guidelin
nontranspl
host
throughout
live
lung
transplant
recipi
increas
risk
infecti
complic
immedi
postop
period
appropri
antimicrobi
prophylaxi
knowledg
time
risk
infecti
complic
aggress
appropri
treatment
infect
decreas
morbid
mortal
popul
mani
infecti
complic
includ
bacteri
viral
fungal
infect
confer
increas
risk
bo
lead
caus
death
lung
recipi
year
transplant
continu
investig
regard
ideal
antimicrobi
prophylaxi
immunosuppress
regimen
allow
clinician
care
lung
transplant
recipi
minim
risk
infect
maxim
allograft
function
limit
reject
minim
advers
effect
associ
prolong
antimicrobi
therapi
